PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) reported a mixed review for its annual performance for drugs and devices covering the period from July 2016 to June 2017 compared to the previous year. Although the agency approved roughly the same number of new chemical entities (NCEs) during 2016 to 2017, approval timelines rose compared to the previous year. Even so, the agency said it reviewed all drugs and devices within the specified legislated time frames.